Developing a PTSD Therapeutic – Phase 3 Clinical Development

Time: 11:55 am
day: Day Two

Details:

  • Targeting disturbed sleep in PTSD to facilitate recovery
  • Role of time-since-trauma in treatment responsiveness
  • Trimodal mechanism of action of cyclobenzaprine; enhancement by dynamic diurnal pharmacokinetic delivery

Speakers: